GSK
Science unites against disease
London, United Kingdom
GSK plc is a British multinational pharmaceutical and biotechnology company specializing in the research, development, manufacturing, and commercialization of prescription medicines and vaccines. Formed in 2000 from the merger of Glaxo Wellcome and SmithKline Beecham, GSK has since demerged its consumer healthcare business to focus exclusively on biopharmaceuticals, with its global headquarters in London, England.
How We Help
Problem Statement
To address various diseases and health challenges by discovering, developing, and delivering innovative medicines and vaccines across critical therapeutic areas.
Core Technology
R&D strategy and pipeline centered on four core therapeutic areas, leveraging understanding of inflammatory mechanisms and the immune system.
Key Differentiators
Leader in HIV research with an industry-leading pipeline, broadest infectious diseases portfolio in the industry, and a recent strategic focus exclusively on biopharmaceuticals after demerging its consumer healthcare business.
Clinical Focus
Respiratory, immunology, and inflammation; Oncology; HIV; Infectious diseases.
Target Customers
Healthcare providers, patients (via prescription)
Product Stage
Mature
Company Info
- Business Model
- B2B
- Founded
- 2000
- Website
- gsk.com
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
13 phase III readouts in 2024. FDA approvals 2024-2025: Exdensur (severe asthma), RSV vaccine Arexvy (expanded indication), Penmenvy (5-in-1 meningococcal), Blujepa (first-in-class UTI antibiotic), Blenrep (multiple myeloma), Nucala (COPD). Pipeline: 69 compounds total, 18 in phase III/registration.
MedStartr Index Score
?What do you think of GSK?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.